# EDGAR Filing Document

**Accession Number:** 0002044725
**File Stem:** 0001876264-25-000004
**Filing Date:** 2025-11
**Character Count:** 5874
**Document Hash:** b8f06a22dcbb269831f5dce7cf89e5fb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001876264-25-000004.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001876264-25-000004

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251105

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LSP 7 Cooperative UA
- **CENTRAL INDEX KEY:** 0001876264

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42938
- **FILM NUMBER:** 251455680

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** JOHANNES VERMEERPLEIN 9
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31206645500

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** JOHANNES VERMEERPLEIN 9
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7

**FORMER NAME:**
- **FORMER CONFORMED NAME:** LSP Cooperative UA
- **DATE OF NAME CHANGE:** 20210802
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evommune, Inc.
- **CENTRAL INDEX KEY:** 0002044725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 850742575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 223-7745

**MAIL ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LSP 7 Cooperative UA<br><sub>(Last) (First) (Middle)</sub><br>JOHANNES VERMEERPLEIN 9<br><sub>(Street)</sub><br>AMSTERDAM, P7 1071 DV<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Evommune, Inc. [ EVMN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-11-05 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 1947477 | <sup>(1)</sup> | D<sup>(2)</sup> |  |
| Series B Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 646587 | <sup>(3)</sup> | D<sup>(2)</sup> |  |
| Series C Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 773069 | <sup>(4)</sup> | D<sup>(2)</sup> |  |

---

### Footnotes:

(1) The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ()"IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.

(2) The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.

(3) The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.

(4) The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.

**Signature:** By LSP 7 Management B.V., its director, By /s/ Martijn Kleijwegt, Managing Director  
**Date:** 2025-11-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**